FDA approves Lilly’s Ebglyss dosing every eight weeks for atopic dermatitis maintenance

Eli Lilly and Company

Eli Lilly and Company

LLY

0.00
  • FDA cleared an every-eight-week maintenance regimen for Lilly’s EBGLYSS in moderate-to-severe atopic dermatitis.
  • Label covers patients aged 12+ weighing at least 88 pounds, using a single 250 mg injection per maintenance dose.
  • Update enables as few as six maintenance injections per year, following an initial loading and induction schedule.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: DE66067) on June 09, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.